- Home
- URGN
URGN
UroGen Pharma Ltd.
as 07-26-2024 4:00pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 673.5M | IPO Year: | 2017 |
| Target Price: | $42.88 | AVG Volume (30 days): | 507.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.60 - $24.13 | Next Earning Date: | 08-08-2024 |
| Revenue: | $84,302,000 | Revenue Growth: | 24.00% |
| Revenue Growth (this year): | 18.68% | Revenue Growth (next year): | 58.90% |
Stock Insider Trading Activity of UroGen Pharma Ltd. (URGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schoenberg Mark | URGN | Chief Medical Officer | Jun 10 '24 | Sell | $13.08 | 5,153 | $67,401.24 | 144,284 | SEC Form 4 |
| Schoenberg Mark | URGN | Chief Medical Officer | Mar 18 '24 | Sell | $14.05 | 12,000 | $168,600.00 | 139,437 | SEC Form 4 |
| Schoenberg Mark | URGN | Chief Medical Officer | Jan 31 '24 | Sell | $15.78 | 1,137 | $17,941.86 | 149,423 | SEC Form 4 |
| Schoenberg Mark | URGN | Chief Medical Officer | Jan 31 '24 | Sell | $15.78 | 758 | $11,961.24 | 149,998 | SEC Form 4 |
| Schoenberg Mark | URGN | Chief Medical Officer | Jan 31 '24 | Sell | $15.78 | 1,894 | $29,887.32 | 151,437 | SEC Form 4 |
| Smith Jason Drew | URGN | General Counsel | Jan 31 '24 | Sell | $15.78 | 417 | $6,580.26 | 18,824 | SEC Form 4 |
| Smith Jason Drew | URGN | General Counsel | Jan 31 '24 | Sell | $15.78 | 1,248 | $19,693.44 | 20,076 | SEC Form 4 |
| Smith Jason Drew | URGN | General Counsel | Jan 31 '24 | Sell | $15.78 | 3,328 | $52,515.84 | 23,414 | SEC Form 4 |
| Schoenberg Mark | URGN | Chief Medical Officer | Jan 31 '24 | Sell | $15.74 | 1,137 | $17,896.38 | 149,423 | SEC Form 4 |
| Schoenberg Mark | URGN | Chief Medical Officer | Jan 31 '24 | Sell | $15.74 | 758 | $11,930.92 | 149,998 | SEC Form 4 |
| Schoenberg Mark | URGN | Chief Medical Officer | Jan 31 '24 | Sell | $15.74 | 1,894 | $29,811.56 | 151,437 | SEC Form 4 |
| Smith Jason Drew | URGN | General Counsel | Jan 31 '24 | Sell | $15.74 | 417 | $6,563.58 | 18,824 | SEC Form 4 |
| Smith Jason Drew | URGN | General Counsel | Jan 31 '24 | Sell | $15.74 | 1,248 | $19,643.52 | 20,076 | SEC Form 4 |
| Smith Jason Drew | URGN | General Counsel | Jan 31 '24 | Sell | $15.74 | 3,328 | $52,382.72 | 23,414 | SEC Form 4 |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
Investor's Business Daily
a month ago
UroGen Pharma Stock Earns 91 RS Rating
Business Wire
a month ago
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire
a month ago
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Zacks
a month ago
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
Investor's Business Daily
a month ago
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
MT Newswires
a month ago
Sector Update: Health Care Stocks Ease Late Afternoon
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Thursday Afternoon
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.